John V Heymach Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

2/2024	Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.
2/2024	Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
2/2024	Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma.
1/2024	Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
11/2023	BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
11/2023	Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
11/2023	Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
11/2023	Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
10/2023	Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
10/2023	Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John V Heymach Research Topics

Disease

208	Neoplasms (Cancer) 04/2024 - 09/2004
148	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 03/2006
75	Lung Neoplasms (Lung Cancer) 01/2024 - 06/2004
26	Neoplasm Metastasis (Metastasis) 10/2023 - 09/2012
24	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2024 - 06/2004
23	Adenocarcinoma of Lung 10/2023 - 10/2006
14	Disease Progression 01/2024 - 05/2009
12	Squamous Cell Carcinoma of Head and Neck 01/2023 - 06/2010
11	Hypoxia (Hypoxemia) 01/2021 - 02/2007
10	Carcinogenesis 09/2023 - 01/2012
7	Melanoma (Melanoma, Malignant) 01/2022 - 04/2010
7	Adenocarcinoma 03/2021 - 07/2015
6	Pneumonia (Pneumonitis) 11/2023 - 01/2019
6	Breast Neoplasms (Breast Cancer) 12/2018 - 12/2008
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021 - 10/2017
5	Brain Neoplasms (Brain Tumor) 01/2021 - 06/2008
5	Exanthema (Rash) 01/2020 - 07/2010
4	Bites and Stings (Sting) 12/2023 - 01/2019
4	Malignant Mesothelioma 10/2020 - 06/2008
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 04/2011
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2015 - 05/2009
3	Pancreatic Neoplasms (Pancreatic Cancer) 11/2023 - 05/2014
3	COVID-19 11/2021 - 01/2021
3	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 07/2011
3	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 09/2004
3	Carcinoma (Carcinomatosis) 01/2020 - 10/2006
3	Ovarian Neoplasms (Ovarian Cancer) 04/2017 - 01/2007
3	Leukemia 01/2017 - 05/2012
3	Colorectal Neoplasms (Colorectal Cancer) 01/2013 - 01/2010

Drug/Important Bio-Agent (IBA)

36	Biomarkers (Surrogate Marker)IBA 04/2024 - 05/2007
31	Proteins (Proteins, Gene)FDA Link 12/2023 - 05/2008
30	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2016
24	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 05/2005
22	ErbB Receptors (EGF Receptor)IBA 01/2023 - 07/2006
18	Tyrosine Kinase InhibitorsIBA 09/2023 - 05/2007
15	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 07/2006
15	vandetanib (ZD6474)IBA 04/2016 - 07/2006
13	CytokinesIBA 01/2023 - 01/2010
13	Phosphotransferases (Kinase)IBA 10/2022 - 12/2007
12	LigandsIBA 03/2023 - 09/2012
11	PlatinumIBA 02/2024 - 08/2011
11	RNA (Ribonucleic Acid)IBA 02/2024 - 02/2016
11	Bevacizumab (Avastin)FDA Link 07/2022 - 03/2006
11	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 02/2016
11	Angiogenesis InhibitorsIBA 10/2019 - 09/2004
10	Docetaxel (Taxotere)FDA Link 02/2024 - 01/2007
9	Carboplatin (JM8)FDA LinkGeneric 02/2024 - 11/2008
9	Circulating Tumor DNAIBA 01/2022 - 03/2016
9	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2012
8	NivolumabIBA 10/2023 - 01/2018
8	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023 - 10/2017
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 02/2007
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2012 - 09/2004
7	IpilimumabIBA 10/2023 - 12/2019
7	Paclitaxel (Taxol)FDA LinkGeneric 02/2023 - 11/2008
7	AntigensIBA 01/2023 - 05/2014
7	Gefitinib (Iressa)FDA Link 05/2009 - 07/2006
6	Cell-Free Nucleic AcidsIBA 01/2024 - 01/2007
6	osimertinibIBA 11/2023 - 12/2018
6	B7-H1 AntigenIBA 11/2023 - 02/2016
6	HM781-36BIBA 01/2023 - 10/2019
6	Messenger RNA (mRNA)IBA 01/2020 - 05/2008
5	durvalumabIBA 02/2024 - 01/2022
5	Sorafenib (BAY 43-9006)FDA Link 02/2023 - 06/2011
5	pembrolizumabIBA 01/2023 - 01/2020
5	AntibodiesIBA 01/2023 - 04/2011
5	Peptides (Polypeptides)IBA 01/2022 - 03/2014
4	Transcription Factors (Transcription Factor)IBA 03/2024 - 08/2009
4	ChemokinesIBA 03/2023 - 07/2011
4	NucleotidesIBA 01/2022 - 08/2013
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2018 - 11/2013
4	Cetuximab (Erbitux)FDA Link 12/2013 - 07/2006
3	Etoposide (VP 16)FDA LinkGeneric 02/2024 - 12/2023
3	atezolizumabIBA 02/2024 - 01/2021
3	InterleukinsIBA 01/2022 - 03/2010
3	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 09/2012
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2021 - 03/2010
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 05/2012
3	Protons (Proton)IBA 01/2020 - 01/2017
3	Small Interfering RNA (siRNA)IBA 01/2020 - 04/2017
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020 - 08/2013
3	cediranib (AZD2171)IBA 10/2019 - 08/2007
3	MicroRNAs (MicroRNA)IBA 01/2019 - 08/2014
3	EnzymesIBA 01/2019 - 01/2010
3	pazopanib FDA Link 01/2018 - 03/2010
3	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2017 - 09/2008
3	Sunitinib (Sutent)FDA Link 11/2012 - 05/2007
3	afliberceptIBA 11/2011 - 12/2008
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2011 - 01/2005
2	tepotinibIBA 08/2023 - 01/2020
2	CrizotinibIBA 08/2023 - 02/2023
2	Everolimus FDA Link 02/2023 - 07/2015

Therapy/Procedure

100	Therapeutics 02/2024 - 01/2005
45	Drug Therapy (Chemotherapy) 02/2024 - 06/2004
42	Radiotherapy 02/2024 - 04/2011
39	Immunotherapy 02/2024 - 01/2016
9	Neoadjuvant Therapy 10/2023 - 01/2018
5	Aftercare (After-Treatment) 11/2022 - 09/2016
4	Chemoradiotherapy 01/2023 - 01/2013
3	Proton Therapy 02/2024 - 01/2018